Theriva Biologics Progresses VIRAGE Phase 2B Trial Of VCN-01 In Combination With Chemotherapy As A First-line Therapy For Metastatic Pancreatic Ductal Adenocarcinoma, Patient Dosing Initiated In U.S., Complete Enrollment Expected In Q1 2024
Portfolio Pulse from Benzinga Newsdesk
Theriva Biologics has initiated patient dosing in the U.S. for its VIRAGE Phase 2B trial of VCN-01 in combination with chemotherapy as a first-line therapy for metastatic pancreatic ductal adenocarcinoma. The company expects to complete enrollment by Q1 2024.
August 04, 2023 | 10:59 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Theriva Biologics, potentially linked to TOVX, has initiated a significant clinical trial. The outcome could impact TOVX's future prospects.
The news is about Theriva Biologics, which might be linked to TOVX. The initiation of a significant clinical trial is a crucial step for the company. However, the impact on TOVX's stock price in the short term is uncertain as the trial results are not expected until Q1 2024.
CONFIDENCE 60
IMPORTANCE 70
RELEVANCE 50